These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23190608)

  • 1. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
    Amodio N; Di Martino MT; Foresta U; Leone E; Lionetti M; Leotta M; Gullà AM; Pitari MR; Conforti F; Rossi M; Agosti V; Fulciniti M; Misso G; Morabito F; Ferrarini M; Neri A; Caraglia M; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Cell Death Dis; 2012 Nov; 3(11):e436. PubMed ID: 23190608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
    Che F; Ye X; Wang Y; Ma S; Wang X
    Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
    Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
    Amodio N; Stamato MA; Gullà AM; Morelli E; Romeo E; Raimondi L; Pitari MR; Ferrandino I; Misso G; Caraglia M; Perrotta I; Neri A; Fulciniti M; Rolfo C; Anderson KC; Munshi NC; Tagliaferri P; Tassone P
    Mol Cancer Ther; 2016 Jun; 15(6):1364-75. PubMed ID: 27196750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.
    Amodio N; Bellizzi D; Leotta M; Raimondi L; Biamonte L; D'Aquila P; Di Martino MT; Calimeri T; Rossi M; Lionetti M; Leone E; Passarino G; Neri A; Giordano A; Tagliaferri P; Tassone P
    Cell Cycle; 2013 Dec; 12(23):3650-62. PubMed ID: 24091729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol Inhibits Diabetic-Induced Müller Cells Apoptosis through MicroRNA-29b/Specificity Protein 1 Pathway.
    Zeng K; Wang Y; Yang N; Wang D; Li S; Ming J; Wang J; Yu X; Song Y; Zhou X; Deng B; Wu X; Huang L; Yang Y
    Mol Neurobiol; 2017 Aug; 54(6):4000-4014. PubMed ID: 27311771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.
    Fulciniti M; Amodio N; Bandi RL; Cagnetta A; Samur MK; Acharya C; Prabhala R; D'Aquila P; Bellizzi D; Passarino G; Adamia S; Neri A; Hunter ZR; Treon SP; Anderson KC; Tassone P; Munshi NC
    Blood Cancer J; 2016 Jan; 6(1):e380. PubMed ID: 26771806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
    Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
    Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
    Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S; Boise LH; Lee KP; Nikiforov MA
    Blood; 2012 Feb; 119(6):1450-8. PubMed ID: 22144178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
    Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
    David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
    Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
    Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-29b inhibits the progression of multiple myeloma through downregulating FOXP1.
    Wang H; Ding Q; Wang M; Guo M; Zhao Q
    Hematology; 2019 Dec; 24(1):32-38. PubMed ID: 30068241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
    Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
    Kikuchi J; Wada T; Shimizu R; Izumi T; Akutsu M; Mitsunaga K; Noborio-Hatano K; Nobuyoshi M; Ozawa K; Kano Y; Furukawa Y
    Blood; 2010 Jul; 116(3):406-17. PubMed ID: 20351311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
    Nara M; Teshima K; Watanabe A; Ito M; Iwamoto K; Kitabayashi A; Kume M; Hatano Y; Takahashi N; Iida S; Sawada K; Tagawa H
    PLoS One; 2013; 8(3):e56954. PubMed ID: 23469177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.